Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class

被引：2
|
作者：
Stelte-Ludwig, Beatrix [1 ]
Schomber, Tibor [1 ]
Izumi, Raquel [2 ]
Wong, Harvey [2 ]
Frigault, Melanie M. [2 ]
Rebstock, Anne-Sophie [1 ]
Ludwig, Sebastian [1 ]
Mithal, Arushi [2 ]
Johnson, Amy J. [2 ]
Hamdy, Ahmed [2 ]
机构：
[1] Vincerx Pharma GmbH, Monheim, Germany
[2] Vincerx Pharma, Palo Alto, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182260
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 36 条
  • [1] VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models
    Stelte-Ludwig, Beatrix
    Clemens, George
    Schomber, Tibor
    Frigault, Melanie M.
    Johnson, Amy J.
    Lerchen, Hans-Georg
    Izumi, Raquel
    Hamdy, Ahmed
    BLOOD, 2022, 140 : 5955 - 5956
  • [2] Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Pemmaraju, Naveen
    Martinelli, Giovanni
    Todisco, Elisabetta
    Lane, Andrew A.
    Acuna-Cruz, Evelyn
    Deconinck, Eric
    Wang, Eunice S.
    Sweet, Kendra
    Rizzieri, David A.
    Marconi, Giovanni
    Mazzarella, Luca
    DeAngelo, Daniel J.
    Montesinos, Pau
    Gigli, Federica
    Erba, Harry P.
    Konopleva, Marina
    Kantarjian, Hagop
    Walter, Roland B.
    Aribi, Ahmed
    Lebon, Delphine
    Levy, Moshe Y.
    Sloss, Callum M.
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Daver, Naval
    BLOOD, 2021, 138
  • [3] IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models
    Adams, Sharlene
    Wilhelm, Alan
    Harvey, Lauren
    Bai, Chen
    Yoder, Nicholas
    Kovtun, Yelena
    Chittenden, Thomas
    Pinkas, Jan
    BLOOD, 2016, 128 (22)
  • [4] IMGN632: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) OF A CD123-TARGETING ANTIBODY WITH A POTENT DNA-ALKYLATOR IS HIGHLY ACTIVE IN PRECLINICAL MODELS OF AML WITH POOR PROGNOSIS
    Kovtun, Y.
    Jones, G.
    Harvey, L.
    Rui, L.
    Audette, C.
    Liu, F.
    Bai, C.
    Wilhelm, A.
    Yoder, N. C.
    Adams, S.
    Goldmacher, V. S.
    Chari, R.
    Chittenden, T.
    HAEMATOLOGICA, 2016, 101 : 222 - 222
  • [5] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Pemmaraju, Naveen
    Martinelli, Giovanni
    Todisco, Elisabetta
    Lane, Andrew A.
    Acuna-Cruz, Evelyn
    Deconinck, Eric
    Wang, Eunice S.
    Sweet, Kendra L.
    Rizzieri, David A.
    Mazzarella, Luca
    DeAngelo, Daniel J.
    Montesinos, Pau
    Tarella, Corrado
    Erba, Harry P.
    Konopleva, Marina
    Kantarjian, Hagop M.
    Sloss, Callum M.
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Daver, Naval
    BLOOD, 2020, 136
  • [6] Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety
    Wang, Yanming
    Liu, Lianqi
    Fan, Shiyong
    Xiao, Dian
    Xie, Fei
    Li, Wei
    Zhong, Wu
    Zhou, Xinbo
    CANCERS, 2020, 12 (03)
  • [7] A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Pemmaraju, Naveen
    Marconi, Giovanni
    Todisco, Elisabetta
    Montesinos, Pau
    Lane, Andrew A.
    Sweet, Kendra
    Wang, Eunice S.
    Deconinck, Eric
    Rizzieri, David A.
    Walter, Roland B.
    Aribi, Ahmed
    Lebon, Delphine
    Levy, Moshe Y.
    Mazzarella, Luca
    Martinelli, Giovanni
    Gigli, Federica
    Erba, Harry P.
    Acuna-Cruz, Evelyn
    Konopleva, Marina
    Kantarjian, Hagop
    Sloss, Callum M.
    Wang, Jiuzhou
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    DeAngelo, Daniel J.
    Daver, Naval
    BLOOD, 2021, 138
  • [8] Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
    Daver, Naval G.
    Montesinos, Pau
    Deangelo, Daniel J.
    Wang, Eunice S.
    Papadantonakis, Nikolaos
    Todisco, Elisabetta
    Sweet, Kendra L.
    Pemmaraju, Naveen
    Lane, Andrew A.
    Torres-Minana, Laura
    Thompson, James E.
    Konopleva, Marina Y.
    Sloss, Callum M.
    Watkins, Krystal
    Bedse, Gaurav
    Du, Yining
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    LANCET ONCOLOGY, 2024, 25 (03): : 388 - 399
  • [9] A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
    Kovtun, Yelena
    Jones, Gregory E.
    Adams, Sharlene
    Harvey, Lauren
    Audette, Charlene A.
    Wilhelm, Alan
    Bai, Chen
    Rui, Lingyun
    Laleau, Rassol
    Liu, Fenghua
    Ab, Olga
    Setiady, Yulius
    Yoder, Nicholas C.
    Goldmacher, Victor S.
    Chari, Ravi V. J.
    Pinkas, Jan
    Chittenden, Thomas
    BLOOD ADVANCES, 2018, 2 (08) : 848 - 858
  • [10] A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells
    Kovtun, Yelena
    Jones, Gregory
    Audette, Charlene
    Harvey, Lauren
    Gerard, Baudouin
    Wilhelm, Alan
    Bai, Chen
    Adams, Sharlene
    Goldmacher, Victor S.
    Chari, Ravi
    Chittenden, Thomas
    BLOOD, 2016, 128 (22)
1234